99mTc mAb-17OH.82(99mTc mAb-17OH.82)

概要

基本信息

药物类型

单克隆抗体

别名

99m-technetium mAb-17OH.82

靶点-

作用机制-

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

乳腺癌

原研机构

Jazz Pharmaceuticals (EUSA Pharma USA), Inc.

在研机构-

非在研机构

Jazz Pharmaceuticals (EUSA Pharma USA), Inc.

最高研发阶段无进展药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 99mTc mAb-17OH.82 相关的临床结果

登录后查看更多信息

100 项与 99mTc mAb-17OH.82 相关的转化医学

登录后查看更多信息

100 项与 99mTc mAb-17OH.82 相关的专利（医药）

登录后查看更多信息

1

项与 99mTc mAb-17OH.82 相关的文献（医药）

1997-04-01·European Journal of Nuclear Medicine

Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: Report of a phase II study

Article

作者: S. A. McQuarrie ; G. D. MacLean ; A. J. B. McEwan ; G. R. Boniface ; K. Golberg

Fifty-three women with clinical evidence of adenocarcinoma of the breast were studied with technetium-99m labelled monoclonal antibody (MAb) 170H.82 at protein doses of 1, 2 and 4 mg. An overall per lesion efficacy of 83.5% sensitivity and 97.7% positive predictive value was obtained. Efficacy appears higher in lesions restricted to the breast and local regional disease than systemic metastases. For the 2 mg dose the breast/local regional disease efficacy was 90% sensitivity and 90.2% positive predictive value. The biodistribution of this MAb was best represented by a two-compartment model with a distribution-phase half-life of 4.0+/-1.4 h, followed by an elimination-phase half-life of 39.6+/-6.6 h. In all six patients studied, the critical organ was the kidney, with a mean radiation absorbed dose of 37+/-6.9 mGy/GBq. The accuracy of this imaging technique allows the development of diagnostic strategies for the routine use of the compound in patients with breast cancer.

100 项与 99mTc mAb-17OH.82 相关的药物交易

登录后查看更多信息